Coronavirus Disease-19 (COVID-19) is characterized as a new highly contagious pandemic disease that has been challenging health managers, professionals and the entire population to face and control this infection. Many alternative compassionate-use therapies were used in patients, although the results of their studies had not been published. From this perspective, the present study aims to describe the pharmaceutical care provided to patients with suspected or diagnosed COVID-19, in line with the protocols, guidelines and clinical studies that have been developed during this period. This is a descriptive, retrospective and observational study, carried out from March to June 2020, in a tertiary hospital in Salvador, Bahia. Data related to clinical activities provided by the clinical pharmacist were assessed, such as drug reconciliations, pharmaceutical interventions, pharmacotherapeutic follow-up, as well as problems related to medications identified in the medical records and prescriptions to hospitalized patients. Of the 241 assessed patients, approximately 75% received some pharmaceutical care that contributed to a positive outcome in the patients’ clinical condition. The clinical pharmacist’s performance brings benefits to the care provided to the patient and, thus, the development of their activities together with the multidisciplinary team in health services is essential.